Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks G C, Gaffney P, Battistutta D, Frost C, Lang C, Russell A
Epidemiology and Population Health Unit, Queensland Institute of Medical Research, Brisbane, University of Queensland, Australia.
Lancet. 1999 Aug 28;354(9180):723-9. doi: 10.1016/S0140-6736(98)12168-2.
The use of sunscreens on the skin can prevent sunburn but whether long-term use can prevent skin cancer is not known. Also, there is evidence that oral betacarotene supplementation lowers skin-cancer rates in animals, but there is limited evidence of its effect in human beings.
In a community-based randomised trial with a 2 by 2 factorial design, individuals were assigned to four treatment groups: daily application of a sun protection factor 15-plus sunscreen to the head, neck, arms, and hands, and betacarotene supplementation (30 mg per day); sunscreen plus placebo tablets; betacarotene only; or placebo only. Participants were 1621 residents of Nambour in southeast Queensland, Australia. The endpoints after 4.5 years of follow-up were the incidence of basal-cell and squamous-cell carcinomas both in terms of people treated for newly diagnosed disease and in terms of the numbers of tumours that occurred. Analysis of the effect of sunscreen was based only on skin cancers that developed on sites of daily application. All analyses were by intention to treat.
1383 participants underwent full skin examination by a dermatologist in the follow-up period. 250 of them developed 758 new skin cancers during the follow-up period. There were no significant differences in the incidence of first new skin cancers between groups randomly assigned daily sunscreen and no daily sunscreen (basal-cell carcinoma 2588 vs 2509 per 100,000; rate ratio 1.03 [95% CI 0.73-1.46]; squamous-cell carcinoma 876 vs 996 per 100,000; rate ratio 0.88 [0.50-1.56]). Similarly, there was no significant difference between the betacarotene and placebo groups in incidence of either cancer (basal-cell carcinoma 3954 vs 3806 per 100,000; 1.04 [0.73-1.27]; squamous-cell carcinoma 1508 vs 1146 per 100,000; 1.35 [0.84-2.19]). In terms of the number of tumours, there was no effect on incidence of basal-cell carcinoma by sunscreen use or by betacarotene but the incidence of squamous-cell carcinoma was significantly lower in the sunscreen group than in the no daily sunscreen group (1115 vs 1832 per 100,000; 0.61 [0.46-0.81]).
There was no harmful effect of daily use of sunscreen in this medium-term study. Cutaneous squamous-cell carcinoma, but not basal-cell carcinoma seems to be amenable to prevention through the routine use of sunscreen by adults for 4.5 years. There was no beneficial or harmful effect on the rates of either type of skin cancer, as a result of betacarotene supplementation.
在皮肤上使用防晒霜可预防晒伤,但长期使用是否能预防皮肤癌尚不清楚。此外,有证据表明口服补充β-胡萝卜素可降低动物的皮肤癌发病率,但在人类中的作用证据有限。
在一项采用2×2析因设计的社区随机试验中,个体被分为四个治疗组:每天对头、颈、手臂和手部涂抹防晒系数为15及以上的防晒霜,并补充β-胡萝卜素(每日30毫克);涂抹防晒霜加安慰剂片;仅补充β-胡萝卜素;或仅用安慰剂。参与者为澳大利亚昆士兰州东南部楠伯的1621名居民。随访4.5年后的终点是基底细胞癌和鳞状细胞癌的发病率,包括新诊断疾病接受治疗的人数以及发生的肿瘤数量。对防晒霜效果的分析仅基于日常涂抹部位发生的皮肤癌。所有分析均采用意向性分析。
1随访期间有1383名参与者接受了皮肤科医生的全面皮肤检查。其中250人在随访期间发生了758例新的皮肤癌。随机分配每日使用防晒霜组和不每日使用防晒霜组之间,首次新发皮肤癌的发病率无显著差异(基底细胞癌每100,000人分别为2588例和2509例;率比1.03[95%CI0.73 - 1.46];鳞状细胞癌每100,000人分别为876例和996例;率比0.88[0.50 - 1.56])。同样,β-胡萝卜素组和安慰剂组在两种癌症的发病率上也无显著差异(基底细胞癌每100,000人分别为3954例和3806例;1.04[0.73 - 1.27];鳞状细胞癌每100,000人分别为1508例和1146例;1.35[0.84 - 2.19])。就肿瘤数量而言,使用防晒霜或β-胡萝卜素对基底细胞癌的发病率没有影响,但防晒霜组鳞状细胞癌的发病率显著低于不每日使用防晒霜组(每100,000人分别为1115例和1832例;0.61[0.46 - 0.81])。
在这项中期研究中,每日使用防晒霜没有有害影响。成人日常使用防晒霜4.5年似乎可预防皮肤鳞状细胞癌,但不能预防基底细胞癌。补充β-胡萝卜素对两种类型皮肤癌的发病率均无有益或有害影响。